<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Edinburgh Research Explorer Exploring the clonal evolution of CD133/aldehydedehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Ilary</forename><surname>Ruscito #</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Gynecology</orgName>
								<orgName type="department" key="dep2">European Competence Center for Ovarian Cancer</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Campus Virchow Klinikum, Augustenburger Platz 1</addrLine>
									<postCode>D-13353</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Gynecology, Obstetrics and Urology</orgName>
								<orgName type="institution">Sapienza University of Rome</orgName>
								<address>
									<settlement>Rome</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Department of Experimental Medicine</orgName>
								<orgName type="institution">Sapienza University of Rome</orgName>
								<address>
									<settlement>Rome</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Dan</forename><forename type="middle">Cacsire</forename><surname>Castillo-Tong</surname></persName>
							<affiliation key="aff3">
								<orgName type="department" key="dep1">Department of Obstetrics and Gynecology</orgName>
								<orgName type="department" key="dep2">Comprehensive Cancer Center</orgName>
								<orgName type="institution">Medical University of Vienna</orgName>
								<address>
									<addrLine>Waehringer Guertel 18-20</addrLine>
									<postCode>A-1090</postCode>
									<settlement>Vienna</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ignace</forename><surname>Vergote</surname></persName>
							<affiliation key="aff4">
								<orgName type="department" key="dep1">Division of Gynaecological Oncology</orgName>
								<orgName type="department" key="dep2">Department of Gynaecology and Obstetrics</orgName>
								<orgName type="institution" key="instit1">Leuven Cancer Institute</orgName>
								<orgName type="institution" key="instit2">Universitaire Ziekenhuizen Leuven</orgName>
								<orgName type="institution" key="instit3">Katholieke Universiteit Leuven</orgName>
								<address>
									<addrLine>Herestraat 49</addrLine>
									<postCode>B-3000</postCode>
									<settlement>Leuven</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Iulia</forename><surname>Ignat</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Gynecology</orgName>
								<orgName type="department" key="dep2">European Competence Center for Ovarian Cancer</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Campus Virchow Klinikum, Augustenburger Platz 1</addrLine>
									<postCode>D-13353</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mandy</forename><surname>Stanske</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Institute of Pathology</orgName>
								<orgName type="institution">Charite Medical University</orgName>
								<address>
									<addrLine>Campus Mitte</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Adriaan</forename><surname>Vanderstichele</surname></persName>
							<affiliation key="aff4">
								<orgName type="department" key="dep1">Division of Gynaecological Oncology</orgName>
								<orgName type="department" key="dep2">Department of Gynaecology and Obstetrics</orgName>
								<orgName type="institution" key="instit1">Leuven Cancer Institute</orgName>
								<orgName type="institution" key="instit2">Universitaire Ziekenhuizen Leuven</orgName>
								<orgName type="institution" key="instit3">Katholieke Universiteit Leuven</orgName>
								<address>
									<addrLine>Herestraat 49</addrLine>
									<postCode>B-3000</postCode>
									<settlement>Leuven</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ram</forename><forename type="middle">N</forename><surname>Ganapathi</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Cancer Pharmacology</orgName>
								<orgName type="institution" key="instit1">Levine Cancer Institute</orgName>
								<orgName type="institution" key="instit2">Carolinas HealthCare System</orgName>
								<address>
									<settlement>Charlotte</settlement>
									<region>NC</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jacek</forename><surname>Glajzer</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Gynecology</orgName>
								<orgName type="department" key="dep2">European Competence Center for Ovarian Cancer</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Campus Virchow Klinikum, Augustenburger Platz 1</addrLine>
									<postCode>D-13353</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Hagen</forename><surname>Kulbe</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Gynecology</orgName>
								<orgName type="department" key="dep2">European Competence Center for Ovarian Cancer</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Campus Virchow Klinikum, Augustenburger Platz 1</addrLine>
									<postCode>D-13353</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Fabian</forename><surname>Trillsch</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Department of Gynecology and Obstetrics</orgName>
								<orgName type="institution">University of Munich</orgName>
								<address>
									<addrLine>Marchioninistrasse 15</addrLine>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff8">
								<orgName type="department">Department of Gynecology and Gynecologic Oncology</orgName>
								<orgName type="institution">University Medical Center Hamburg-Eppendorf</orgName>
								<address>
									<addrLine>Martinistr. 46</addrLine>
									<settlement>Hamburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff9">
								<orgName type="department">10.Department of Gynecology and Obstetrics</orgName>
								<orgName type="institution">University Medicine of Greifswald</orgName>
								<address>
									<settlement>Greifswald</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Alexander</forename><surname>Mustea</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Caroline</forename><surname>Kreuzinger</surname></persName>
							<affiliation key="aff3">
								<orgName type="department" key="dep1">Department of Obstetrics and Gynecology</orgName>
								<orgName type="department" key="dep2">Comprehensive Cancer Center</orgName>
								<orgName type="institution">Medical University of Vienna</orgName>
								<address>
									<addrLine>Waehringer Guertel 18-20</addrLine>
									<postCode>A-1090</postCode>
									<settlement>Vienna</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Pierluigi</forename><surname>Benedetti Panici</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Gynecology, Obstetrics and Urology</orgName>
								<orgName type="institution">Sapienza University of Rome</orgName>
								<address>
									<settlement>Rome</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Charlie</forename><surname>Gourley</surname></persName>
							<affiliation key="aff10">
								<orgName type="institution" key="instit1">Nicola Murray Centre for Ovarian Cancer Research</orgName>
								<orgName type="institution" key="instit2">University of Edinburgh Cancer Research UK Centre</orgName>
								<orgName type="institution" key="instit3">MRC IGMM</orgName>
								<orgName type="institution" key="instit4">Western General Hospital</orgName>
								<address>
									<addrLine>Crewe Road South</addrLine>
									<postCode>EH4 2XR</postCode>
									<settlement>Edinburgh</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Hani</forename><surname>Gabra</surname></persName>
							<affiliation key="aff11">
								<orgName type="department">Department of Surgery and Cancer</orgName>
								<orgName type="institution">Ovarian Cancer Action Research Centre</orgName>
							</affiliation>
							<affiliation key="aff12">
								<orgName type="institution">Imperial College London</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mirjana</forename><surname>Kessler</surname></persName>
							<affiliation key="aff13">
								<orgName type="department" key="dep1">Department of Molecular Biology</orgName>
								<orgName type="department" key="dep2">Max Planck Institute for Infection Biology</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jalid</forename><surname>Sehouli</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Gynecology</orgName>
								<orgName type="department" key="dep2">European Competence Center for Ovarian Cancer</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Campus Virchow Klinikum, Augustenburger Platz 1</addrLine>
									<postCode>D-13353</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Silvia</forename><surname>Darb-Esfahani</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Institute of Pathology</orgName>
								<orgName type="institution">Charite Medical University</orgName>
								<address>
									<addrLine>Campus Mitte</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Elena</forename><forename type="middle">Ioana</forename><surname>Braicu</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Gynecology</orgName>
								<orgName type="department" key="dep2">European Competence Center for Ovarian Cancer</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Campus Virchow Klinikum, Augustenburger Platz 1</addrLine>
									<postCode>D-13353</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><roleName>MD</roleName><forename type="first">Ilary</forename><surname>Ruscito</surname></persName>
							<email>ilary.ruscito@uniroma1.it</email>
						</author>
						<author>
							<affiliation key="aff14">
								<orgName type="department" key="dep1">Department of Gynecology</orgName>
								<orgName type="department" key="dep2">European Competence Center for Ovarian Cancer</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Campus Virchow Klinikum, Augustenburger Platz 1</addrLine>
									<postCode>D-13353</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Edinburgh Research Explorer Exploring the clonal evolution of CD133/aldehydedehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">1B0C01C46B3BB701DE23994EA1BDC3D9</idno>
					<idno type="DOI">10.1016/j.ejca.2017.04.016</idno>
					<note type="submission">Link to publication record in Edinburgh Research Explorer</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:32+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Peer reviewed version Ovarian Cancer</term>
					<term>CD133</term>
					<term>ALDH1</term>
					<term>Aldehyde dehydrogenase-1</term>
					<term>cancer stem-like cell</term>
					<term>BRCA</term>
					<term>prognosis</term>
					<term>survival</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent highgrade serous ovarian cancer (HGSOC).</s><s>A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium',</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Take down policy</head><p><s>The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation.</s><s>If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>INTRODUCTION</head><p><s>Ovarian cancer (OC) remains the most lethal gynecologic malignancy <ref type="bibr" target="#b0">[1]</ref>.</s><s>Advances in cancer genomics, epigenomics and proteomics has led to the understanding that OC is a heterogeneous group of different tumors displaying distinct phenotypes and etiology <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b2">3]</ref>.</s><s>The current dichotomous OC classification <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b4">5]</ref>groups these tumors in two distinct categories: Type I (low-grade serous-papillary, low-grade endometrioid, mucinous and clear-cell carcinomas) and Type II (high-grade serous-papillary, highgrade endometroid, carcinosarcomas and undifferentiated tumors).</s><s>Type II OCs show a more aggressive biological behavior, are diagnosed at advanced stage and are chromosomally highly unstable.</s><s>Among them, high-grade serous OC (HGSOC) accounts for around 80% of all OC deaths <ref type="bibr" target="#b2">[3]</ref>.</s><s>The identification of predictive biomarkers is pivotal for designing new treatment strategies able to reduce HGSOCrelated mortality.</s><s>In this context, the cancer stem-like cell (CSC) theory represents one model to investigate OC heterogeneity.</s><s>This hypothesis, supported by increased evidence acquired in the last decade, proposes that, within OC tissues, a small population of cells has an increased capacity for self-renewal, tumorigenesis and differentiation <ref type="bibr" target="#b5">[6]</ref>.</s><s>In multiple experimental studies CSCs showed to increase potential of tumorigenesis, metastasis/invasion, neoangiogenesis and chemoresistance <ref type="bibr" target="#b6">[7,</ref><ref type="bibr" target="#b7">8]</ref>and have been often correlated with a poor prognosis <ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref>.</s></p><p><s>Several potential CSC markers have been identified in OC samples <ref type="bibr">[14]</ref><ref type="bibr" target="#b15">[15]</ref>.</s><s>Among them, aldehyde dehydrogenase-1 (ALDH1) and CD133 are currently the best characterized for ovarian CSCs.</s><s>Their expression on the cell surface is associated with increased tumorigenesis and self-renewal capability <ref type="bibr" target="#b16">[16]</ref><ref type="bibr" target="#b17">[17]</ref><ref type="bibr" target="#b18">[18]</ref>.</s><s>Nevertheless, the clonal evolution of CSCs throughout the course of disease, from primary (pOC) to recurrent (rOC) OC, has not been elucidated yet and information about the changes in CSC presence within the tumor after relapse is still lacking.</s></p><p><s>The aim of this study was to investigate the evolution of CSC biomarkers CD133 and ALDH1 expression in a large series of paired primary and recurrent HGSOCs.</s><s>Inclusion criteria were: having experienced at least one OC relapse for which having been subjected to at least one palliative surgery.</s><s>Exclusion criterion was: no cancer tissue available from both pOC and rOC.</s><s>Approval from each local ethics committee was obtained (EK207/2003,ML2524,05/Q0406/178,EK130113,06/S1101/16).</s><s>OC tissue samples were collected during primary cytoreduction and at the surgery for relapse.</s><s>All included samples underwent central histopathological assessment to confirm the diagnosis of HGSOC and to evaluate the tissue quality and tumor contain.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>MATERIALS AND METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Sample</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Immunohistochemistry</head><p><s>Immunohistochemical staining was performed on tissue microarrays (TMAs).</s></p><p><s>Slides were deparaffinized in xylol, rehydrated in graded alcohol and boiled in a pressure cooker for 5 minutes in citrate buffer (pH=6) for ALDH1 staining or in EDTA (pH=9) for CD133 staining.</s><s>Mouse anti-human ALDH1-antibody (clone 44;BD Transduction Laboratories,Franklin Lakes, NJ,USA) and mouse anti-human CD133/1-antibody (AC133 clone;Miltenyi-Biotech, BergischGladbach,Germany) were diluted 1:500 and incubated on the slides for 60 minutes at room temperature.</s></p><p><s>Bound antibodies were visualized using DAKO Real Detection System and DAB+ (3,3 ′ -diaminobenzidine;DAKO,Glostrup,Denmark) as a chromogen.</s><s>Finally, the slides were co-stained with hematoxylin.</s></p><p><s>CD133 stained samples were assessed basing on the number of stained tumor cells.</s></p><p><s>Samples were classified as "CD133-negative"(&lt;10% CD133 positive tumor cells) and "CD133-positive"(&gt;10% CD133-positive tumor cells) <ref type="bibr" target="#b19">[19]</ref><ref type="bibr" target="#b20">[20]</ref>.</s></p><p><s>For ALDH1 staining evaluation, as previously published <ref type="bibr" target="#b21">[21]</ref><ref type="bibr" target="#b22">[22]</ref>, the number of stained tumor cells (0%=0;1-10%=1;11-50%=2;&gt;50%=3) was multiplied with the intensity of staining(negative=0;weak=1;moderate=2;strong=3), resulting in a semiquantitive immunoreactivity score(IRS) that ranged from 0 to 9. For further analysis, samples were classified "ALDH1-negative", for absent or weak focal staining(IRS=0-1), or "ALDH1-positive", for ALDH1-high tumor expression(IRS=2-9).</s></p><p><s>All samples were evaluated independently by two co-authors (IR and SDE).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Clinical Data and Follow-up</head><p><s>Patients' clinical data and information on 52 patients' germline and/or somatic BRCA status were retrieved from OCTIPS Consortium database <ref type="bibr" target="#b23">[23]</ref><ref type="bibr" target="#b24">[24]</ref>.</s><s>Platinumresistance and platinum-sensitivity were defined, according to GCIG, as relapse occurring before or after six months following the last platinum-based chemotherapy, respectively <ref type="bibr" target="#b25">[25]</ref>.</s><s>Recurrence was defined basing on RECIST Criteria <ref type="bibr">[26]</ref>.</s><s>A sole CA125 serum elevation was not considered relapse <ref type="bibr" target="#b28">[27]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical Analysis</head><p><s>Statistical analysis was performed using SPSS version 22.0(SPSS Inc, Chicago, IL, USA).</s><s>To assess the difference between pOCs and rOCs in terms of biomarker expression, the correlation test (Spearman coefficient, 2-tailed) and the "Wilcoxon signed rank" non-parametric test for related samples were applied.</s><s>Correlation of CD133 and ALDH1 tumor expression with patients' clinico-pathological categorical data was assessed using the Fisher's exact test.</s><s>Patients' progression-free interval(PFI), progression-free survival (PFS) and overall survival(OS) were determined by Kaplan-Meier analysis (Log-Rank test).PFI represented the time interval from the last adjuvant chemotherapy to relapse, whereas progression-free survival (PFS) was the time interval between first recurrence diagnosis and tumor progression.</s><s>For univariate and multivariate survival analyses, the Cox regression model was used.</s><s>Multivariable models were performed among variables reporting a p-value≤0.1 in univariate analysis.</s><s>P values≤0.05</s><s>were considered statistically significant.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head><p><s>Primary and recurrent intra-patient paired tumor samples derived from 112 HGSOC patients were analyzed for CD133 and ALDH1 expression.</s><s>Patients' characteristics are listed in Table <ref type="table" target="#tab_6">1</ref>.</s></p><p><s>Immunohistochemistry staining showed that ALDH1 and CD133 proteins were localized to the cytoplasm(Fig1,Fig.</s><s><ref type="figure">3</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CD133 expression.</head><p><s>CD133-positive (CD133 + ) staining was significantly more frequent among pOCs[55/112(49.1%)]</s><s>compared to rOCs[38/112(33.9%)],</s><s>p=0.030(Fisher's exact test,Fig.</s><s><ref type="figure">1a,1c</ref>).</s><s>Investigation of sequential changes in CD133+ expression in paired tumors, with a correlation test (Spearman coefficient) between pOCs and rOCs, demonstrated a significant correlation (p=0.001,Spearman</s><s>coefficient 0.306).</s></p><p><s>Furthermore, pairwise testing revealed a significant shift from higher frequency of CD133 + cells in pOCs to lower levels in the paired recurrent samples (p&lt;0.0001,</s><s>Wilcoxon test;Fig.</s><s><ref type="figure">2</ref>), thus indicating significantly higher rates of CD133 + cells in pOCs compared to rOCs.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ALDH1 expression.</head><p><s>Distribution of ALDH1 IRS in pOCs and rOCs is shown in Fig. <ref type="figure">3a,3d</ref>.</s><s>ALDH-1 positive tumors were found in 37.5%(42/112) and 36.6%(41/112) of primary and recurrent samples, respectively (p=1,Fisher's exact test,Fig.</s><s><ref type="figure">3b,3e</ref>).</s><s>A trend for significant correlation between pOCs and rOCs ALDH1-expression levels was seen (p=0.059,Spearman</s><s>coefficient 0.179).</s><s>Pairwise analysis showed no tendency towards a change of IRS values to higher or lower levels in recurrences (p=0.988,Wilcoxon</s><s>test;Fig.</s><s><ref type="figure">4</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CD133/ALDH1 co-expression.</head><p><s>Co-expression of both CSCs biomarkers was detected in 23.2%(26/112) of pOCs and in 15.2%(17/112) of rOCs(p=0.174,Fisher's</s><s>exact test).</s><s>Among 26 patients reporting CD133/ALDH1 co-expression in pOCs, 22(84.6%)</s><s>lost this pathological characteristic in relapse situation.</s><s>Of the 17 patients presenting biomarker coexpression in rOC, 13(76.5%)</s><s>showed no co-expression in pOC.</s><s>Consequently, 4/112 patients (3.6%) showed CD133/ALDH1 co-expression in both pOC and rOC: two of them were platinum-resistant and two were platinum-sensitive.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CSCs biomarkers and clinico-pathological factors</head><p><s>We analyzed the correlation of ALDH1 and/or CD133 tumor expression patterns in pOCs with patients´ clinico-pathological characteristics.</s><s>All primary CD133 + patients were diagnosed at FIGO III/IV stage (p=0.006).</s><s>No correlation was observed between other clinico-pathological factors and ALDH1 and/or CD133 tumor expression(Tab.2).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Survival</head><p><s>CD133 positivity in pOCs was significantly associated with poor PFI and OS (Fig. <ref type="figure">5a,5b</ref>).</s><s>In particular, CD133 + and CD133patients reported median OS of 51 and 71 months (HR:1.713;95%CI:1.076-2.727;p=0.02)</s><s>and median PFI of 9 and 17 months (HR:1.477;95%CI:1.006-2.170;p=0.04).</s><s>PFS after recurrence was not significantly different (p=0.868,Fig.</s><s><ref type="figure">5c</ref>) between patients with CD133+ and CD133or between (p=0.252,Fig.</s><s><ref type="figure">5f</ref>) patients with ALDH1+ and ALDH1rOC.</s></p><p><s>Median OS for ALDH1 + and ALDH1patients was 52 and 64 months, respectively (p=0.402) and median PFI-1 was 9 and 17 months, respectively (p=0.199)(Fig.</s><s><ref type="figure">5d,5e</ref>).</s><s>ALDH1/CD133 co-expression in pOCs was found to significantly affect HGSOC patients' outcome.</s><s>A significant decrease in OS and PFI has been found in patients co-expressing ALDH1/CD133 in primary tissue (46 and 9 months, respectively) compared to patients without biomarker co-expression (68 and 17 months, respectively) (p=0.019,Fig.</s><s><ref type="figure">5g</ref>;p=0.015,Fig.</s><s><ref type="figure">5h</ref>).</s><s>No significant difference in PFS after relapse was observed between patients who reported CD133/ALDH1 co-expression or no co-expression in rOC(p=0.898,Fig.</s><s><ref type="figure">5i</ref>).</s></p><p><s>On multivariate analysis, the co-expression of ALDH1 and CD133 in pOC, rather than the single expression of one biomarker, was identified to be an independent prognostic factor for both PFI (HR:1.638;95%CI:1.033-2.598;p=0.036)</s><s>and OS (HR:1.707;95%CI:1.012-2.881;p=0.045) in HGSOC(Tab.3,4).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Outliers' sub-analysis</head><p><s>"Outliers" were considered patients for whom the highest difference between pOC and rOC could be detected in CD133+cell rate.</s><s>Three patients were identified: two reported a difference in CD133+cell rate of -90%(from 90% of CD133+cells at pOC to 0% at rOC); the first one was a platinum-resistant patient with PFI of 2 months and OS of 14 months; the second one was a platinum-sensitive patient with PFI of 7 months and OS of 9 months.</s><s>The third patient showed a difference in CD133+cell rate of +70%(from 0% of CD133+ at pOC cells to 70% in rOC) with PFI of 15 months (platinum-sensitive) and OS of 44 months.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CSC biomarker expression and BRCA status</head><p><s>In order to investigate if BRCA mutations could influence CSC biomarker expression, a subgroup analysis was carried out among 52 patients, whose germline and/or somatic BRCA status (assessed on pOC and rOC) was available <ref type="bibr" target="#b24">[24]</ref>.</s><s>40.4% of tested patients (21/52) had a somatic BRCA mutation in both pOCs and rOCs: 16/52(30.8%)</s><s>were BRCA1-mutated (mBRCA1) and 5/52(9.6%)</s><s>were BRCA2-mutated (mBRCA2)(Tab.5).</s></p><p><s>No significant difference in CD133 and/or ALDH1 expression was found between BRCA-wild type (BRCA-WT) and BRCA-mutant (mBRCA1/2) tumors(Tab.6).</s></p><p><s>Among BRCA-WT patients, no correlation between pOCs and rOCs in CD133+ expression was observed (p=0.088,Spearman</s><s>coefficient 0.312).</s><s>Furthermore, in accordance with results observed in the whole population, paired testing revealed a significant shift from higher levels in pOCs to lower levels in the rOCs (p&lt;0.0001,Wilcoxon</s><s>test;Fig.</s><s><ref type="figure">6a</ref>).</s><s>In contrast, among mBRCA1/2 patients, no correlation between pOCs and rOCs (p=0.493,Spearman</s><s>coefficient 0.158), or a tendency towards a change in CD133+ expression was observed (p=0.167,Wilcoxon</s><s>test;Fig.</s><s><ref type="figure">6b</ref>).</s></p><p><s>Regarding ALDH1 expression, among BRCA-WT patients no correlation between pOCs and rOCs in ADH1 IRS was found (p=0.986,Spearman</s><s>coefficient 0.003), as well as no change in paired testing (p=0.895,Wilcoxon</s><s>test;Fig.</s><s><ref type="figure">7a</ref>); also for mBRCA1/2 patients no difference was observed in ALDH1-IRS between primary and recurrent patients (p=0.410,Spearman</s><s>coefficient 0.190;p=0.385,Wilcoxon</s><s>test;Fig.</s><s><ref type="figure">7b</ref>).</s></p><p><s>Among BRCA-WT patients, only 1/31 patient (3.2%) showed CD133/ALDH1 coexpression in both pOCs and rOCs.</s><s>In 3/31(9.7%)</s><s>patients the co-expression was evidenced in rOCs but not in pOCs.</s><s>90% of patients (9/10) reporting CD133/ALDH1 co-expression in pOC lost biomarker co-expression at tumor relapse.</s><s>Also for mBRCA1/2 patients, only 1/21(4.8%)</s><s>patient showed CD133/ALDH1 coexpression in both pOC and rOC.</s><s>Two patients (9.5%) had co-expression at recurrent rather than at primary disease.</s><s>The difference between BRCA-WT and mBRCA1/2 patients in terms of co-expression loss at rOC was not significant (4/5 vs 9/10,p=1, Fisher's exact test).</s></p><p><s>Considering patients who were CD133+ and/or ALDH1+ at pOC, no significant difference could be detected in PFI and OS among BRCA-WT vs mBRCA1/2 cases(Fig.</s><s><ref type="figure">8</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p><s>In the Era of Precision Medicine, huge steps have been taken in the understanding of HGSOC biology.</s><s>In this tumor setting, the role of CSC and its clonal evolution during subsequent disease relapse has been relatively unexplored.</s></p><p><s>This study investigated the changes in CSC biomarkers CD133 and ALDH1 expression in primary and recurrent HGSOCs and showed that CD133+CSCs are significantly more represented in pOCs rather than rOCs, whereas no significant changes in terms of ALDH1 expression levels occurred at disease relapse.</s><s>Furthermore, CD133 positivity in pOCs significantly correlates with poor survival, while co-expression of both CD133 and ALDH1 in primary samples independently predicted poor PFI and OS in HGSOC patients.</s></p><p><s>In 2015, Zhou published a meta-analysis <ref type="bibr" target="#b29">[28]</ref>, which investigated the prognostic value of immunohistochemical CD133 expression in OC.</s><s>Pooled data derived from 1050 patients from 8 studies showed that CD133 positivity significantly correlates with advanced FIGO stage at diagnosis and with worse OS, in accordance with our findings, although our population was restricted to HGSOC.</s></p><p><s>Other recent meta-analysis demonstrated that also ALDH1 is a promising prognostic biomarker for breast <ref type="bibr" target="#b8">[9]</ref>, head/neck <ref type="bibr" target="#b9">[10]</ref>, lung <ref type="bibr" target="#b10">[11]</ref>and colorectal cancer <ref type="bibr" target="#b11">[12]</ref> but its predictive or prognostic role in OC is still controversial <ref type="bibr" target="#b12">[13,</ref><ref type="bibr" target="#b30">[29]</ref><ref type="bibr" target="#b31">[30]</ref><ref type="bibr" target="#b32">[31]</ref>.</s><s>In contrast to CD133, ALDH1 expression is usually low or negative in serous OC compared to other cancer histotype and more frequent in low FIGO stage tumors <ref type="bibr" target="#b12">[13,</ref><ref type="bibr" target="#b30">29]</ref>.</s><s>Previously, Liebscher <ref type="bibr" target="#b21">[21]</ref> investigated the prognostic impact of ALDH1 expression in a homogeneous group of primary HGSOC patients and demonstrated that ALDH1 was an independent prognostic factor for OS.</s><s>These results differ from our findings, since in our population ALDH1 did not have an impact on patients' survival.</s></p><p><s>Nevertheless, in Liebscher's population the frequency of FIGO Stage I-II cases was higher than in our population (11.5% vs 7.2%), while the number of optimally cytoreduced patients was lower (66.3%</s><s>vs 80.4%).</s></p><p><s>Silva <ref type="bibr" target="#b33">[32]</ref> showed that the co-expression of CD133 and ALDH1 correlated with significant worse PFI and OS in a small cohort of 56 ovarian cancer patients.</s><s>These results were in accordance with our findings in a larger HGSOC population.</s></p><p><s>To our knowledge, this is the first study analyzing the evolution of CSC markers in the largest cohort of primary and recurrent HGSOC patients.</s><s>Furthermore, the subanalysis on patients with known BRCA status increases the value of the findings by taking into consideration the genetic influence of BRCA status on patients' survival <ref type="bibr" target="#b34">[33]</ref><ref type="bibr" target="#b35">[34]</ref>and provides a first evidence of the correlation between tumorinitiating cells and homologous recombination deficieny.</s><s>Limitation of the study was the lack of information regarding BRCA1/2 status on all enrolled patients.</s><s>The analysis on a cohort of 52 patients could not provide definitive conclusions for this issue.</s></p><p><s>Interestingly, we observed that 84.6% of our patients' cohort reporting CD133/ALDH1 co-expression in pOC lost this pathological characteristic at relapse.</s><s>Nevertheless, while CSC biomarker expression is significantly correlated with poor prognosis, it is enigmatic why in a recurrent setting, which represents a more aggressive step of the disease compared to primary disease, CSCs are less frequently encountered.</s><s>Theoretically, CSCs were expected to be much more frequent in rOC than in the pOC.</s><s>We hypothesize that the reduction in CSC biomarker expression does not represent a reduction in CSC number within the tumor sample, but might be the result of cellular reprogramming occurring in the CSC itself, which might lead to the loss of CSC biomarker expression.</s><s>Studies on this issue are still lacking.</s></p><p><s>This study shows that CD133 and ALDH1 as biomarkers can have influence on HGSOC patients' survival and for the first time suggests that they might be caused by a phenotypical change during the course of the disease similarly to non stem-like cancer cells.</s><s>However, the need for recurrent tumor tissue to be analyzed implied that this cohort of samples might be not the most representative one for ovarian cancer patients, due to the fact that most of patients had a platinum sensitive relapse, and surgical approach at relapse was feasible.</s><s>For this reason, general conclusion for the whole recurrent ovarian cancer setting cannot currently be drawn.</s></p><p><s>Another limitation of the study is that these biomarkers, in particular ALDH1, are broadly expressed, not only by CSCs.</s><s>The identification of CSC is actually sure only based on the capacity to build spheroids, on tumor xenograft assay and on serial transplantation assay, which require fresh tumor tissue.</s><s>Nevertheless, IHC allowed to analyze a large cohort of paired tumor tissues and to observe that there is a change in CSC-associated biomarker expression between primary and relapse disease.</s></p><p><s>Further investigations on larger cohort of paired pOC and rOC samples are warranted, potentially expanding the scope with inclusion of further candidate CSC markers and with evaluation of CSCs behavior following neoadjuvant chemotherapy <ref type="bibr" target="#b32">[31,</ref><ref type="bibr" target="#b36">[35]</ref><ref type="bibr" target="#b37">[36]</ref>, in order to reduce mortality of one of the most deadly malignancies of our time.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>LEGEND TO TABLES AND FIGURES</head></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc><div><p><s>Collection 224 paired samples from 112 HGSOC patients were collected during primary and secondary tumor debulking.</s><s>Patients were included consecutively and have been treated between 1985 and 2013 through primary cytoreduction followed by platinumbased chemotherapy.</s><s>Patients, retrospectively selected from the OCTIPS (Ovarian Cancer Therapy-Innovative Models Prolong Survival, Agreement No.279113-2) Consortium database, were treated for both pOC and rOC in one of the European Gynecologic Oncology Referral Centers of the following Institutions: Charité Universitätsmedizin Berlin,Germany; Katholieke Universiteit Leuven,Belgium; Imperial College, London,UK; University of Edinburgh,UK.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head> Figure 1 :Figure 2 :</head><label>12</label><figDesc><div><p><s>CD133 immunohistochemistry staining.</s><s>Primary tumors, CD133+ (a) and CD133-(b) samples; recurrent tumors, CD133+ (c) and CD133-(d) samples.</s><s>CD133+ cell rates among primary and recurrent tumors (box plot -a -and line plot -b).</s><s> Figure 3: ALDH1 immunohistochemistry staining.</s><s>ALDH1 IRS at primary (a) and recurrent (d) tumors.</s><s>Primary tumors, ALDH1+ (b) and ALDH1-(c) samples; recurrent tumors, ALDH1+ (e) and ALDH1-(f) samples.</s><s> Figure 4: ALDH1 IRS among primary and recurrent tumors (box plot -a -and line plot -b).</s><s> Figure 5: CD133 and/or ALDH1 status in primary (a, b, d, e, g, h) and recurrent (c, f, i) samples and survival.</s><s> Figure 6: CD133+ cell rates among primary and recurrent tumors (box plot, BRCA-WT-a -and box plot mBRCA1/2 -b).</s><s> Figure 7: ALDH1 IRS among primary and recurrent tumors (box plot BRCA-WT-a -and box plot mBRCA1/2 -b).</s><s> Figure 8: CD133+ and/or ALDH1+ and survival in BRCA-WT and mBRCA1/2 patients (primary tumors).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head> Table 1 :</head><label>1</label><figDesc><div><p><s>Patients' characteristics </s></p></div></figDesc><table /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2 :</head><label>2</label><figDesc><div><p><s>Association of CSCs biomarkers expression with patients' clinicopathological characteristics (primary tumors).</s></p></div></figDesc><table><row><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 3 :</head><label>3</label><figDesc><div><p><s>Multivariate analysis for PFI </s></p></div></figDesc><table /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 4 :</head><label>4</label><figDesc><div><p><s>Multivariate analysis for OS Table5: patients' germline and/or somatic (primary and recurrent tumor)</s></p></div></figDesc><table><row><cell>BRCA status.</cell></row><row><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 6 :</head><label>6</label><figDesc><div><p><s>Association of CSCs biomarkers expression with patients' BRCA status (primary tumors).</s></p></div></figDesc><table /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6"><head>Table 1</head><label>1</label><figDesc></figDesc><table /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_7"><head>Table 2</head><label>2</label><figDesc></figDesc><table><row><cell>Clinico-pathological factors</cell><cell>Total N°</cell><cell cols="2">CD133</cell><cell></cell><cell cols="2">ALDH1</cell><cell></cell><cell cols="3">CD133 and ALDH1 coexpression</cell></row><row><cell></cell><cell></cell><cell>Positive (%)</cell><cell>Negative (%)</cell><cell>P</cell><cell>Positive (%)</cell><cell>Negative (%)</cell><cell>P</cell><cell>Positive (%)</cell><cell>Negative (%)</cell><cell>P</cell></row><row><cell>Patients' Age</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>&lt; 56y</cell><cell>54</cell><cell>27 (50%)</cell><cell>27 (50%)</cell><cell>0.855</cell><cell>18 (33%)</cell><cell>36 (67%)</cell><cell>0.288</cell><cell>11 (20%)</cell><cell>43 (80%)</cell><cell>0.492</cell></row><row><cell>≥ 56y</cell><cell>58</cell><cell>28 (48%)</cell><cell>30 (52%)</cell><cell></cell><cell>25 (43%)</cell><cell>33 (57%)</cell><cell></cell><cell>15 (26%)</cell><cell>43 (74%)</cell><cell></cell></row><row><cell>FIGO STAGE</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>I/II</cell><cell>8</cell><cell>0</cell><cell>8 (100%)</cell><cell>0.006</cell><cell>3 (38%)</cell><cell>5 (62%)</cell><cell>1.000</cell><cell>0</cell><cell>8 (100%)</cell><cell>0.194</cell></row><row><cell>III/IV</cell><cell>104</cell><cell>55 (53%)</cell><cell>49 (47%)</cell><cell></cell><cell>40 (39%)</cell><cell>64 (61%)</cell><cell></cell><cell>26 (25%)</cell><cell>78 (75%)</cell><cell></cell></row><row><cell>RESIDUAL TUMOR</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>AFTER FIRST</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>CYTOREDUCTIVE</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>SURGERY</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>No residual</cell><cell>90</cell><cell>42 (47%)</cell><cell>48 (53%)</cell><cell>0.346</cell><cell>35 (39%)</cell><cell>55 (61%)</cell><cell>1.000</cell><cell>20 (22%)</cell><cell>70 (78%)</cell><cell>0.586</cell></row><row><cell>Any residual</cell><cell>22</cell><cell>13 (59%)</cell><cell>9 (41%)</cell><cell></cell><cell>8 (36%)</cell><cell>14 (64%)</cell><cell></cell><cell>6 (27%)</cell><cell>16 (73%)</cell><cell></cell></row><row><cell>PLATINUM</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>SENSITIVITY</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>STATUS AFTER</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>PRIMARY</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>TREATMENT</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Platinum sensitive</cell><cell>90</cell><cell>43 (48%)</cell><cell>47 (52%)</cell><cell>0.439</cell><cell>33 (37%)</cell><cell>57 (63%)</cell><cell>0.303</cell><cell>19 (21%)</cell><cell>71 (79%)</cell><cell>0.357</cell></row><row><cell>Platinum resistant</cell><cell>18</cell><cell>7 (39%)</cell><cell>11 (61%)</cell><cell></cell><cell>9 (50%)</cell><cell>9 (50%)</cell><cell></cell><cell>6 (33%)</cell><cell>12 (67%)</cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_8"><head>Table 3</head><label>3</label><figDesc></figDesc><table><row><cell cols="2">PROGRESSION FREE INTERVAL</cell><cell></cell><cell></cell></row><row><cell></cell><cell cols="2">UNIVARIATE ANALYSIS</cell><cell cols="2">MULTIVARIATE ANALYSIS</cell></row><row><cell></cell><cell>HR (95% CI)</cell><cell>P</cell><cell>HR (95% CI)</cell><cell>P</cell></row><row><cell>Age</cell><cell cols="2">1.003 (0.983-1.024) 0.774</cell><cell></cell></row><row><cell>FIGO Stage (III/IV vs I/II)</cell><cell cols="2">2.019 (0.907-4.496) 0.085</cell><cell cols="2">1.856 (0.826-4.169) 0.134</cell></row><row><cell>Residual Tumor (any residual vs no residual)</cell><cell cols="2">1.026 (0.625-1.684) 0.919</cell><cell></cell></row><row><cell>CD133/ALDH1 coexpression (positive vs negative)</cell><cell cols="2">1.729 (1.093-2.733) 0.019</cell><cell cols="2">1.638 (1.033-2.598) 0.036</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_9"><head>Table 5</head><label>5</label><figDesc></figDesc><table><row><cell>PATIENT ID</cell><cell>GERMLINE BRCA STATUS</cell><cell>SOMATIC BRCA STATUS -PRIMARY TUMOR</cell><cell>SOMATIC BRCA STATUS -RECURRENT TUMOR</cell></row><row><cell>B001</cell><cell>mBRCA1</cell><cell>mBRCA1</cell><cell>mBRCA1</cell></row><row><cell>B002</cell><cell>WT</cell><cell>WT</cell><cell>WT</cell></row><row><cell>B003</cell><cell>WT</cell><cell>WT</cell><cell>WT</cell></row><row><cell>B006</cell><cell>N/A</cell><cell>WT</cell><cell>WT</cell></row><row><cell>B007</cell><cell>N/A</cell><cell>WT</cell><cell>WT</cell></row><row><cell>B009</cell><cell>N/A</cell><cell>WT</cell><cell>WT</cell></row><row><cell>B012</cell><cell>N/A</cell><cell>WT</cell><cell>WT</cell></row><row><cell>B015</cell><cell>N/A</cell><cell>WT</cell><cell>WT</cell></row><row><cell>B019</cell><cell>WT</cell><cell>mBRCA2</cell><cell>mBRCA2</cell></row><row><cell>B021</cell><cell>N/A</cell><cell>WT</cell><cell>WT</cell></row><row><cell>B022</cell><cell>N/A</cell><cell>WT</cell><cell>WT</cell></row><row><cell>B024</cell><cell>mBRCA1</cell><cell>mBRCA1</cell><cell>mBRCA1</cell></row><row><cell>B025</cell><cell>N/A</cell><cell>WT</cell><cell>WT</cell></row><row><cell>B026</cell><cell>N/A</cell><cell>WT</cell><cell>WT</cell></row><row><cell>B028</cell><cell>mBRCA1</cell><cell>mBRCA1</cell><cell>mBRCA1</cell></row><row><cell>B029</cell><cell>mBRCA1</cell><cell>mBRCA1</cell><cell>mBRCA1</cell></row><row><cell>B030</cell><cell>N/A</cell><cell>WT</cell><cell>WT</cell></row><row><cell>B032</cell><cell>WT</cell><cell>WT</cell><cell>WT</cell></row><row><cell>B037</cell><cell>N/A</cell><cell>WT</cell><cell>WT</cell></row><row><cell>B041</cell><cell>mBRCA1</cell><cell>mBRCA1</cell><cell>mBRCA1</cell></row><row><cell>B044</cell><cell>N/A</cell><cell>WT</cell><cell>WT</cell></row><row><cell>B045</cell><cell>N/A</cell><cell>mBRCA1</cell><cell>mBRCA1</cell></row><row><cell>B048</cell><cell>WT</cell><cell>WT</cell><cell>WT</cell></row><row><cell>B050</cell><cell>WT</cell><cell>WT</cell><cell>WT</cell></row><row><cell>B051</cell><cell>N/A</cell><cell>mBRCA2</cell><cell>mBRCA2</cell></row><row><cell>B052</cell><cell>WT</cell><cell>WT</cell><cell>WT</cell></row><row><cell>B053</cell><cell>N/A</cell><cell>WT</cell><cell>WT</cell></row><row><cell>B054</cell><cell>N/A</cell><cell>WT</cell><cell>WT</cell></row><row><cell>B062</cell><cell>N/A</cell><cell>WT</cell><cell>WT</cell></row><row><cell>B063</cell><cell>N/A</cell><cell>mBRCA2</cell><cell>mBRCA2</cell></row><row><cell>B065</cell><cell>WT</cell><cell>WT</cell><cell>WT</cell></row><row><cell>B068</cell><cell>N/A</cell><cell>mBRCA1</cell><cell>mBRCA1</cell></row><row><cell>B069</cell><cell>N/A</cell><cell>WT</cell><cell>WT</cell></row><row><cell>B071</cell><cell>N/A</cell><cell>mBRCA1</cell><cell>mBRCA1</cell></row><row><cell>B077</cell><cell>mBRCA2</cell><cell>mBRCA2</cell><cell>mBRCA2</cell></row><row><cell>B080</cell><cell>mBRCA2</cell><cell>mBRCA2</cell><cell>mBRCA2</cell></row><row><cell>B081</cell><cell>WT</cell><cell>mBRCA1</cell><cell>mBRCA1</cell></row><row><cell>B082</cell><cell>N/A</cell><cell>mBRCA1</cell><cell>mBRCA1</cell></row><row><cell>B085</cell><cell>N/A</cell><cell>mBRCA1</cell><cell>mBRCA1</cell></row><row><cell>B087</cell><cell>mBRCA1</cell><cell>mBRCA1</cell><cell>mBRCA1</cell></row><row><cell>B088</cell><cell>N/A</cell><cell>WT</cell><cell>WT</cell></row><row><cell>B090</cell><cell>N/A</cell><cell>mBRCA1</cell><cell>mBRCA1</cell></row><row><cell>B093</cell><cell>N/A</cell><cell>WT</cell><cell>WT</cell></row><row><cell>B094</cell><cell>N/A</cell><cell>mBRCA1</cell><cell>mBRCA1</cell></row><row><cell>B097</cell><cell>N/A</cell><cell>mBRCA1</cell><cell>mBRCA1</cell></row><row><cell>B098</cell><cell>N/A</cell><cell>WT</cell><cell>WT</cell></row><row><cell>B099</cell><cell>N/A</cell><cell>WT</cell><cell>WT</cell></row><row><cell>B100</cell><cell>N/A</cell><cell>WT</cell><cell>WT</cell></row><row><cell>L007</cell><cell>WT</cell><cell>WT</cell><cell>WT</cell></row><row><cell>L010</cell><cell>WT</cell><cell>WT</cell><cell>WT</cell></row><row><cell>L017</cell><cell>WT</cell><cell>WT</cell><cell>WT</cell></row><row><cell>L020</cell><cell>mBRCA1</cell><cell>mBRCA1</cell><cell>mBRCA1</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_10"><head>Table 6</head><label>6</label><figDesc></figDesc><table><row><cell>BRCA status</cell><cell>Total N°</cell><cell></cell><cell>CD133</cell><cell></cell><cell cols="2">ALDH1</cell><cell></cell><cell cols="3">CD133 and ALDH1 coexpression</cell></row><row><cell></cell><cell></cell><cell>Positive (%)</cell><cell>Negative (%)</cell><cell>P</cell><cell>Positive (%)</cell><cell>Negative (%)</cell><cell>P</cell><cell>Positive (%)</cell><cell>Negative (%)</cell><cell>P</cell></row><row><cell>BRCA-WT mBRCA1/2</cell><cell>31 21</cell><cell>21 (68%) 13 (62%)</cell><cell>10 (32%) 8 (38%)</cell><cell>0.769</cell><cell>13 (42%) 7 (33%)</cell><cell>18 (58%) 14 (67%)</cell><cell>0.575</cell><cell>10 (32%) 5 (24%)</cell><cell>21 (68%) 16 (76%)</cell><cell>0.551</cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Download date: 18. May. 2022</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements.</head><p><s>This work was supported by European Community's Seventh Framework Program under grant agreement No. 279113-2 (OCTIPS).</s><s>The documentation of clinical and patient's data was managed with "AlcedisTRIAL the web based documentation system" of Alcedis GmbH, Winchesterstr.</s><s>3, 35394 Giessen, Germany.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conflict of interest statement.</head><p><s>All Authors declare no conflict of interest.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012</title>
		<author>
			<persName><forename type="first">J</forename><surname>Ferlay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Steliarova-Foucher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lortet-Tieulent</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rosso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Coebergh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Comber</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cancer</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="1374" to="1403" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Rethinking ovarian cancer: recommendations for improving outcomes</title>
		<author>
			<persName><forename type="first">S</forename><surname>Vaughan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">I</forename><surname>Coward</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Bast</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Berchuck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Berek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Brenton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Cancer</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="719" to="725" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Integrated genomic analyses of ovarian carcinoma</title>
		<author>
			<persName><forename type="first">Cgar</forename><surname>Network</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">474</biblScope>
			<biblScope unit="page" from="609" to="615" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">New insights into the pathogenesis of serous ovarian cancer and its clinical impact</title>
		<author>
			<persName><forename type="first">K</forename><surname>Levanon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Crum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Drapkin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="5284" to="5293" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis</title>
		<author>
			<persName><forename type="first">J</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Fadare</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Xiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Kong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Zheng</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Hematol Oncol</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="issue">8</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">A cell initiating human acute myeloid leukaemia after transplantation into SCID mice</title>
		<author>
			<persName><forename type="first">T</forename><surname>Lapidot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Sirard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Vormoor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Murdoch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hoang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Caceres-Cortes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">367</biblScope>
			<biblScope unit="page" from="645" to="648" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Cancer stem cells: impact, heterogeneity, and uncertainty</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Magee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Piskounova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Morrison</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Cell</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="283" to="296" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Ovarian cancer stem cells: working towards the root of stemness</title>
		<author>
			<persName><forename type="first">R</forename><surname>Foster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Buckanovich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">R</forename><surname>Rueda</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Lett</title>
		<imprint>
			<biblScope unit="volume">338</biblScope>
			<biblScope unit="page" from="147" to="157" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">ALDH1A1 expression correlates with clinicopathologic features and poor prognosis of breast cancer patients: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Lv</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Duan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">J</forename><surname>Yang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Cancer</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">444</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">The prognostic role of the cancer stem cell marker aldehyde dehydrogenase 1 in head and neck squamous cell carcinomas: a meta-analysis</title>
		<author>
			<persName><forename type="first">C</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Sun</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oral Oncol</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page" from="1144" to="1148" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">ALDH1 Expression and the Prognosis of Lung Cancer: A Systematic Review and Meta-Analysis</title>
		<author>
			<persName><forename type="first">D</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Peng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Tan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">H</forename><surname>Hu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Heart Lung Circ</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="780" to="788" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Prognostic Value of Cancer Stem Cell Marker ALDH1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis</title>
		<author>
			<persName><forename type="first">J</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Xia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Yuan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Ma</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">e0145164</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">The expression of aldehyde dehydrogenase 1 (ALDH1) in ovarian carcinomas and its clinicopathological associations: a retrospective study</title>
		<author>
			<persName><forename type="first">R</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Holm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">G</forename><surname>Trope</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Nesland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Suo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Cancer</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page">18</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<monogr>
		<title level="m" type="main">Stem and progenitor-like cells</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Bapat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Mali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">B</forename><surname>Koppikar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">K</forename><surname>Kurrey</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Bapat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Mali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">B</forename><surname>Koppikar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">K</forename><surname>Kurrey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="3025" to="3029" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Cancer stem cells, epithelialmesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma</title>
		<author>
			<persName><forename type="first">X</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Liu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Human Pathol</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="2373" to="2384" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells</title>
		<author>
			<persName><forename type="first">T</forename><surname>Baba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Convery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Matsumura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Whitaker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Kondoh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Perry</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="209" to="218" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">ALDH1-high ovarian cancer stem-like cells can be isolated from serous and clear cell adenocarcinoma cells, and ALDH1 high expression is associated with poor prognosis</title>
		<author>
			<persName><forename type="first">T</forename><surname>Kuroda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Hirohashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Torigoe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Yasuda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Takahashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Asanuma</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page">e65158</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">CD133 expression defines a tumor initiating cell population in primary human ovarian cancer</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Curley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">A</forename><surname>Therrien</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Cummings</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Sergent</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Koulouris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Friel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Stem Cells</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="2875" to="2883" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Expression and clinical significance of CD133 and Notch1 gene in epithelial ovarian carcinoma</title>
		<author>
			<persName><surname>Hz L</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">W</forename><surname>Ys B</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chin J Clinicians (Electronics Edition)</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="2086" to="2088" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Expression of putative stem marker nestin and CD133 in advanced serous ovarian cancer</title>
		<author>
			<persName><forename type="first">Q</forename><surname>Qin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Jia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neoplasma</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="310" to="315" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Liebscher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Prinzler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">V</forename><surname>Sinn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Budczies</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Denkert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Noske</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum Pathol</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="1465" to="1471" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">H</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Hynes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Ginestier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Dontu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Appelman</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer</title>
		<author>
			<persName><forename type="first">S</forename><surname>Lambrechts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Smeets</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Moisse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">I</forename><surname>Braicu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Vanderstichele</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zhao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cancer</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="51" to="64" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Characteristics of homologous recombination deficiency (HRD) in paired primary and recurrent high-grade serous ovarian cancer (HGSOC)</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Sehouli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Timms</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Solimeno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Reid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Lanchbury</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Clinical trials in recurrent ovarian cancer</title>
		<author>
			<persName><forename type="first">M</forename><surname>Friedlander</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Trimble</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tinker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Alberts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Avall-Lundqvist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Brady</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Gynecol Cancer</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="771" to="775" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<monogr>
		<title level="m" type="main">New response evaluation criteria in solid tumours: Revised RECIST guideline</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Eisenhauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Therasse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bogaerts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>Schwartz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Sargent</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ford</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>version 1.1)</note>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Eisenhauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Therasse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bogaerts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>Schwartz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Sargent</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ford</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">European Journal of Cancer</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="228" to="247" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">125 agreed by the Gynecological Cancer Intergroup (GCIG)</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Rustin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Vergote</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Eisenhauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Pujade-Lauraine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Quinn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Thigpen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Gynecol Cancer</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="419" to="423" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Prognostic value of cancer stem cell marker CD133 in ovarian cancer: a meta-analysis</title>
		<author>
			<persName><forename type="first">Q</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Tao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zuo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Clin Exp Med</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="3080" to="3088" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">ALDH1 expression correlates with favorable prognosis in ovarian cancers</title>
		<author>
			<persName><forename type="first">B</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Xue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Rosen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Xiao</forename><forename type="middle">L</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mod Pathol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="817" to="823" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Musashi-1 Expression is a Prognostic Factor in Ovarian Adenocarcinoma and Correlates with ALDH-1 Expression</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">X</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><forename type="middle">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Yang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pathol Oncol Res</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="1133" to="1140" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Accumulation of ALDH1-positive cells after neoadjuvant chemotherapy predicts treatment resistance and prognosticates poor outcome in ovarian cancer</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">H</forename><surname>Ayub</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Keyver-Paik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Debald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Rostamzadeh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Thiesler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Schröder</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncotarget</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="16437" to="16448" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">A</forename><surname>Silva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mclean</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Griffith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Thomas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page" from="3991" to="4001" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer</title>
		<author>
			<persName><forename type="first">D</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Khan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hess</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Shmulevich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Sood</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">306</biblScope>
			<biblScope unit="page" from="1557" to="1565" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Bolton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Chenevix-Trench</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Goh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sadetzki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Ramus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">Y</forename><surname>Karlan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">307</biblScope>
			<biblScope unit="page" from="382" to="389" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">5-Fluorouracil chemotherapy of gastric cancer generates residual cells with properties of cancer stem cells</title>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">Y</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">X</forename><surname>Xie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">A</forename><surname>Du</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">F</forename><surname>Yu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Biol Sci</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="284" to="294" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">T</forename><surname>Mizukami</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kamachi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Mitsuhashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Tsuruga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Hatanaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kamiyama</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
